NewInsight: The AI sell-off compared to well-known stock market crashes

Edwards Lifesciences EW

Edwards Lifesciences is the 205th largest S&P 500 company by market cap, worth $58.7 billion. Its board has 10 directors, 8 of them independent. 7 other officers are on file. At 30 Jun 2026, Vanguard was its largest institutional holder, with 12.2% of the company.

CEO
Bernard J. Zovighian
Chair
Nicholas J. Valeriani
Sector
Health CareHealth Care Equipment
Headquarters
Irvine, California
Founded
1958
Market cap
$58.7B
205th largest, 6 Nov 2026 close
Revenue
$6.1B
Fiscal year 2025
Price to sales
9.7
Market cap over revenue
Employees
16,000
10-K, 31 Dec 2025
Per employee
$3.7M
Market cap over employees
Connections
1
Companies sharing people

Financials

Latest quarter

Q2 2026 figures from Edwards Lifesciences' earnings release.

Filed 23 Jul 2026

Revenue
$1.7B
Up 14% year over year
Net income
$242M
Down 27% year over year
Diluted EPS
$0.42
Down 26% year over year
Operating income
$513M
Up 25% year over year

Reported figures

Figures from the release, against the same period a year earlier.

FigureValueYear earlierChange
Net sales$1.7B$1.5B+14%
Gross profit margin77.5%77.5%0.0 pts
Operating income, net$513M$411M+25%
Net income attributable to Edwards Lifesciences Corporation$242M$333M-27%
Diluted EPS$0.42$0.57-26%
Cash and cash equivalents$2.9B--
Adjusted net income$448M$392M+14%
Adjusted diluted EPS$0.78$0.67+16%
Adjusted gross profit margin77.6%77.6%0.0 pts
Adjusted operating profit margin30%28.2%+1.8 pts
Total debt$600M--

Financial history

Twelve months to 30 Sep 2026, from Edwards Lifesciences' quarterly filings.

Quarters since Dec 2021

Revenue
$6.7B
Up 13% on the year before
Net income
$1.0B
15.3% of revenue
Free cash flow
$1.4B
Operating cash flow less capital spending
P/E
57.5
Market cap over net income

Quarterly results

Each quarter's revenue, net income and free cash flow.

Dec 2021 to Sep 2026

$0$500M$1B$1.5B$2B202120222023202420252026$1.7B

Per employee

Twelve months to 30 Sep 2026, over 16,000 employees in Edwards Lifesciences' latest 10-K.

Revenue
$417K
Operating profit
$90K
21.6% of revenue
Net income
$64K
15.3% of revenue

Edwards Lifesciences' market cap since December 2008

Weekly, up to 6 Nov 2026

Show equal percentage changes as equal steps.
201020122014201620182020202220242026$58.7B

Board and leadership

Board and officers

1 person here also holds roles at other S&P 500 companies.

Board from the proxy filed 26 Mar 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (10)
Nicholas J. ValerianiChairIndependent · since 2014 · Compensation and GovernanceFormer CEO, Gary and Mary West Health Institute Former EVP, Johnson & JohnsonChair2014YesCompensation and Governance69
Bernard J. ZovighianCEONot independent · since 2023CEO2023No58
Leslie C. DavisDirectorIndependent · since 2024 · Compensation and GovernanceCEO and President, University of Pittsburgh Medical CenterDirector2024YesCompensation and Governance67
David T. FeinbergDirectorIndependent · since 2024 · AuditChairman, Oracle Health, Inc.Also at HumanaDirector2024YesAudit64
Kieran GallahueDirectorIndependent · since 2015 · AuditFormer Chairman and CEO, CareFusion CorporationOther boards: Envista HoldingsDirector2015YesAudit62
Leslie S. HeiszDirectorIndependent · since 2016 · Audit (chair)Former Managing Director, Lazard Frères & CoOther boards: Ingram Micro HoldingDirector2016YesAudit (chair)65
Paul A. LavioletteDirectorIndependent · since 2020 · Compensation and Governance (chair)CEO, Pulse Biosciences, Inc., Managing Partner and COO, SV Health Investors LLCOther boards: Pulse BiosciencesDirector2020YesCompensation and Governance (chair)68
Steven R. LorangerDirectorIndependent · since 2016 · Compensation and GovernanceFormer Chairman, President and CEO , ITT CorporationDirector2016YesCompensation and Governance74
Ramona SequeiraDirectorIndependent · since 2020 · AuditFormer President, Global Portfolio Division, Takeda Pharmaceutical CompanyOther boards: Organon & Co. and Novo Nordisk A/SDirector2020YesAudit60
Heisz Leslie StoneDirectorDirector
Officers (7)
Theodora MistrasCVP, Chief Financial OfficerLast filed 10 Jul 2026CVP, Chief Financial Officer
Donald E. Bobo Jr.CVP,Strategy/Corp DevelopmentLast filed 27 May 2026CVP,Strategy/Corp Development
Annette BrulsCvp, EmeaclaLast filed 28 Aug 2026Cvp, Emeacla
Daveen ChopraCVP, TMTT, Surgical & IHFMLast filed 11 Sep 2026CVP, TMTT, Surgical & IHFM
Andrew M. DahlSVP, Corporate ControllerLast filed 14 Sep 2026SVP, Corporate Controller
Daniel J. LippisCvp, TavrLast filed 11 Sep 2026Cvp, Tavr
Wayne MarkowitzCvp, JapacLast filed 14 Sep 2026Cvp, Japac

Companies that share people with Edwards Lifesciences

Each person's title here, then at the other company.

  • Humana HUM
    • David T. Feinberg: Director here, Director there

Owners and trading

Largest institutional holders

Each fund group's share of Edwards Lifesciences. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 33.8% of Edwards Lifesciences.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 6 Nov 2025 to 6 Nov 2026

Directors and officers sold $27.7 million of stock in 43 sales and made no open-market purchases in the 12 months to 6 Nov 2026.

DatePersonTitleTypeSharesValue
8 Oct 2026SaleDaniel J. LippisCvp, TavrCvp, TavrSale619$53K
11 Sep 2026SaleDaniel J. LippisCvp, TavrCvp, TavrSale619$54K
31 Aug 2026SaleAndrew M. DahlSVP, Corporate ControllerSVP, Corporate ControllerSale544$50K
28 Aug 2026SaleAnnette BrulsCvp, EmeaclaCvp, EmeaclaSale2,644$238K
26 Aug 2026SaleDaveen ChopraCVP, TMTT, Surgical & IHFMCVP, TMTT, Surgical & IHFMSale31,800$2.9M
26 Aug 2026SaleWayne MarkowitzCvp, JapacCvp, JapacSale1,240$113K
11 Aug 2026SaleDaniel J. LippisCvp, TavrCvp, TavrSale619$57K
30 Jul 2026SaleWayne MarkowitzCvp, JapacCvp, JapacSale146$13K
28 Jul 2026SaleWayne MarkowitzCvp, JapacCvp, JapacSale9,628$819K
27 Jul 2026SaleBernard J. ZovighianCEOCEOSale2,921$245K

Showing 10 of 43 trades

Trades by members of Congress and officials

Trades members of Congress and senior executive branch officials disclosed, including their families'. Amounts are filed as ranges.

Trades from 27 Oct 2023 to 27 Oct 2026

10 people disclosed 9 purchases and 11 sales of Edwards Lifesciences stock since October 2023.

DateMember or officialTypeAmount
3 Aug 2026Rohit Khanna (House, D-CA)House, D-CA · SoldSale$1,001 to $15,000$1K to $15K
11 May 2026Donald J Trump (President)President · BoughtPurchase$50,001 to $100,000$50K to $100K
13 Apr 2026Rohit Khanna (House, D-CA)House, D-CA · BoughtPurchase$1,001 to $15,000$1K to $15K
10 Apr 2026Donald J Trump (President)President · SoldSale$100,001 to $250,000$100K to $250K
27 Mar 2026Alan Armstrong (Senate, R-OK)Senate, R-OK · BoughtPurchase$1,001 to $15,000$1K to $15K
10 Feb 2026Donald J Trump (President)President · BoughtPurchase$500,001 to $1,000,000$500K to $1M
23 Jan 2026Rohit Khanna (House, D-CA)House, D-CA · SoldSale$1,001 to $15,000$1K to $15K
13 Jan 2026Rohit Khanna (House, D-CA)House, D-CA · SoldSale$1,001 to $15,000$1K to $15K
19 Nov 2025Josh Gottheimer (House, D-NJ)House, D-NJ · SoldSale$1,001 to $15,000$1K to $15K
7 Oct 2025Rohit Khanna (House, D-CA)House, D-CA · SoldSale$1,001 to $15,000$1K to $15K

Showing 10 of 20 trades

Workforce and hiring

Workforce

Headcount at 31 Dec 2025

Employees
16,000

Employees, last 10 fiscal years

Up 7.4% in five years, from 14,900 in 2020 to 16,000 in 2025.

As of December 31, 2025, we had approximately 16,000 employees worldwide, the majority of whom were located in the United States, Singapore, and Costa Rica.
Edwards Lifesciences Form 10-K

Open roles

Jobs listed on Edwards Lifesciences' careers site, each counted once.

Daily, up to 3 Nov 2026

Open roles
358
On 3 Nov 2026
Change
-21
Down 5.5% since 27 Oct 2026
Top function
Sales & Marketing
30% of open roles
Remote
6%
92% do not say

Open roles in detail

27 Oct 2026 to 3 Nov 2026

27 Oct3 Nov358

WARN layoff notices

Notices filed under Edwards Lifesciences' own name or a subsidiary's listed in its 10-K.

Notices from 7 Nov 2023 to 7 Nov 2026

Edwards Lifesciences filed 2 notices covering 193 workers since November 2023.

NoticePlaceWorkersEffective
4 Sep 2024Irvine, CA1928 Nov 2024
4 Sep 2024Santa Ana, CA18 Nov 2024

Timeline

Leadership changes, layoffs and insider sales

7 Nov 2024 to 7 Nov 2026; insider sales from 6 Nov 2025

3 departures and 2 appointments of directors and officers and 11 large insider sales in the last two years.

Left the company or board 3Appointed 2WARN layoff notices 0Large insider sales 11Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Edwards Lifesciences' insider sales.

Events, newest first

Showing 8 of 16 events